EffRx Pharmaceuticals SA, a Freienbach, Switzerland-based specialty pharmaceutical company, raised over CHF2.3m in equity funding.
All funds were raised through existing shareholders.
The company intends to use the funds to launch its first orphan drug clinical trial program as well as to start preparations for a planned IPO.
Led by Christer Rosén, Chairman & CEO, EffRx Pharmaceuticals develops novel therapeutic entities including orphan indications by applying its proprietary technology platform to well characterized molecules.
FinSMEs
13/01/2015